Posted by Michael Wonder on 14 Mar 2017
Senate inquiry to probe the complexity of prostheses pricing
14 March 2017 - AusBiotech is set to give evidence at this week’s Senate Inquiry into the reform of prostheses pricing, which has proven to be a complex and confusing debate on how to best address the system of pricing products on the Prostheses List for implantable medical devices used in private hospitals.
The Inquiry by the Senate Community Affairs References Committee into ‘Price regulation associated with the Prostheses List Framework’, which commences tomorrow, includes in its terms of reference: opportunities to create a more competitive basis for the purchase and reimbursement of prostheses; the cost for privately insured patients versus public hospital patients and the impact on affordability of private health insurance in Australia; the benefits of adopting other pricing mechanisms; and a look at where costs are being generated within the supply chain, with a particular focus on cardiac, Intra Ocular Lens Systems, hips, knees, spine and trauma devices.
